Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 180

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

DNAM-1/CD155 Interactions Promote Cytokine and NK Cell-Mediated Suppression of Poorly Immunogenic Melanoma Metastases

Open access
Chan, Christopher J, Andrews, Daniel M, McLaughlin, Nicole M, Yagita, Hideo, Gilfillan, Susan, Colonna, Marco, Smyth, Mark J·2010·The Journal of Immunology

Abstract

A role for NK cells in therapeutic intervention for hematologic malignancies, such as acute myeloid leukemia and multiple myeloma, and nonhematologic malignancies, such as melanoma, is becoming more apparent. DNAM-1 is an NK cell receptor whose importance in facilitating activation signals received by NK cells in natural and cytokine-driven responses to tumor metastases in vivo is poorly explored. In this study, we used matched tumor lines expressing a variety of relevant ligands, neutralizing monoclonal Abs, and DNAM-1 gene-targeted mice to determine the relative importance of DNAM-1–ligand interactions in controlling tumor metastases. Our results demonstrate that NK cells require DNAM-1 for natural or cytokine (IL-2, IL-12, or IL-21) suppression of tumor metastases or their variants expressing CD70 or CD80. In contrast, DNAM-1 was dispensable when tumor cells were targets of Ab-dependent cellular cytotoxicity or presented ligands for NKG2D. CD155 appeared to be a key ligand recognized by DNAM-1 in NK cell-mediated suppression of metastases, and DNAM-1-mediated suppression coincided with perforin activity. Overall, these data implied a general role for DNAM-1-CD155 interactions in NK cell-mediated killing of tumors, even in the presence of tumor CD70 or CD80 expression, and further defined the optimal efficacy requirements of cytokines that directly activate NK cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4049/jimmunol.0903225

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 48

  1. Kärre, 1986, Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defense strategy., Nature, 319, 675, 10.1038/319675a0 · DOI · Paper page
  2. Smyth, 1999, Perforin is a major contributor to NK cell control of tumor metastasis., J. Immunol., 162, 6658, 10.4049/jimmunol.162.11.6658 · DOI · Paper page
  3. Velardi, 2008, Role of KIRs and KIR ligands in hematopoietic transplantation., Curr. Opin. Immunol., 20, 581, 10.1016/j.coi.2008.07.004 · DOI
  4. Velardi, 2008, Clinical impact of natural killer cell reconstitution after allogeneic hematopoietic transplantation., Semin. Immunopathol., 30, 489, 10.1007/s00281-008-0136-1 · DOI
  5. Davis, 2009, Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial., Clin. Cancer Res., 15, 2123, 10.1158/1078-0432.CCR-08-2663 · DOI
  6. Miller, 2005, Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer., Blood, 105, 3051, 10.1182/blood-2004-07-2974 · DOI · Paper page
  7. Romagne, 2009, Pre-clinical characterization of 1-7F9, a novel human anti-KIR therapeutic antibody that augments NK-mediated killing of tumor cells, Blood, 114, 2667, 10.1182/blood-2009-02-206532 · DOI · Paper page
  8. Bryceson, 2006, Activation, coactivation, and costimulation of resting human natural killer cells., Immunol. Rev., 214, 73, 10.1111/j.1600-065X.2006.00457.x · DOI · Paper page
  9. Shibuya, 1996, DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes., Immunity, 4, 573, 10.1016/S1074-7613(00)70060-4 · DOI · Paper page
  10. Dardalhon, 2005, CD226 is specifically expressed on the surface of Th1 cells and regulates their expansion and effector functions., J. Immunol., 175, 1558, 10.4049/jimmunol.175.3.1558 · DOI
  11. Seth, 2009, Heterogeneous expression of the adhesion receptor CD226 on murine NK and T cells and its function in NK-mediated killing of immature dendritic cells., J. Leukoc. Biol., 86, 91, 10.1189/jlb.1208745 · DOI
  12. Bottino, 2003, Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule., J. Exp. Med., 198, 557, 10.1084/jem.20030788 · DOI · Paper page
  13. Castriconi, 2004, Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction., Cancer Res., 64, 9180, 10.1158/0008-5472.CAN-04-2682 · DOI · Paper page
  14. Fuchs, 2004, Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155)., J. Immunol., 172, 3994, 10.4049/jimmunol.172.7.3994 · DOI · Paper page
  15. Tahara-Hanaoka, 2006, Tumor rejection by the poliovirus receptor family ligands of the DNAM-1 (CD226) receptor., Blood, 107, 1491, 10.1182/blood-2005-04-1684 · DOI
  16. El-Sherbiny, 2007, The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells., Cancer Res., 67, 8444, 10.1158/0008-5472.CAN-06-4230 · DOI · Paper page
  17. Pende, 2006, Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction., Blood, 107, 2030, 10.1182/blood-2005-07-2696 · DOI · Paper page
  18. Bryceson, 2006, Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion., Blood, 107, 159, 10.1182/blood-2005-04-1351 · DOI · Paper page
  19. Raulet, 2003, Roles of the NKG2D immunoreceptor and its ligands., Nat. Rev. Immunol., 3, 781, 10.1038/nri1199 · DOI · Paper page
  20. Hayakawa, 2002, Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin., J. Immunol., 169, 5377, 10.4049/jimmunol.169.10.5377 · DOI · Paper page
  21. Moretta, 2001, Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis., Annu. Rev. Immunol., 19, 197, 10.1146/annurev.immunol.19.1.197 · DOI · Paper page
  22. Kelly, 2002, Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection., Nat. Immunol., 3, 83, 10.1038/ni746 · DOI · Paper page
  23. Kelly, 2002, A role for IFN-γ in primary and secondary immunity generated by NK cell-sensitive tumor-expressing CD80 in vivo., J. Immunol., 168, 4472, 10.4049/jimmunol.168.9.4472 · DOI
  24. Gilfillan, 2008, DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors., J. Exp. Med., 205, 2965, 10.1084/jem.20081752 · DOI · Paper page
  25. Street, 2001, Perforin and interferon-γ activities independently control tumor initiation, growth, and metastasis., Blood, 97, 192, 10.1182/blood.V97.1.192 · DOI · Paper page
  26. Ho, 2002, Costimulation of multiple NK cell activation receptors by NKG2D., J. Immunol., 169, 3667, 10.4049/jimmunol.169.7.3667 · DOI
  27. Smyth, 2001, NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma., Int. Immunol., 13, 459, 10.1093/intimm/13.4.459 · DOI · Paper page
  28. Street, 2007, Host perforin reduces tumor number but does not increase survival in oncogene-driven mammary adenocarcinoma., Cancer Res., 67, 5454, 10.1158/0008-5472.CAN-06-4084 · DOI
  29. Smyth, 2001, Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon γ-dependent natural killer cell protection from tumor metastasis., J. Exp. Med., 193, 661, 10.1084/jem.193.6.661 · DOI · Paper page
  30. Smyth, 2000, The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent., J. Immunol., 165, 2665, 10.4049/jimmunol.165.5.2665 · DOI · Paper page
  31. Brady, 2004, IL-21 induces the functional maturation of murine NK cells., J. Immunol., 172, 2048, 10.4049/jimmunol.172.4.2048 · DOI · Paper page
  32. Tahara-Hanaoka, 2004, Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112)., Int. Immunol., 16, 533, 10.1093/intimm/dxh059 · DOI · Paper page
  33. Smyth, 2004, NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer., J. Exp. Med., 200, 1325, 10.1084/jem.20041522 · DOI · Paper page
  34. Chambers, 1996, Triggering of natural killer cells by the costimulatory molecule CD80 (B7-1), Immunity, 5, 311, 10.1016/S1074-7613(00)80257-5 · DOI · Paper page
  35. Takeda, 2000, CD27-mediated activation of murine NK cells., J. Immunol., 164, 1741, 10.4049/jimmunol.164.4.1741 · DOI
  36. Rosenberg, 2001, Progress in human tumour immunology and immunotherapy., Nature, 411, 380, 10.1038/35077246 · DOI · Paper page
  37. Skak, 2008, Interleukin 21: combination strategies for cancer therapy., Nat. Rev. Drug Discov., 7, 231, 10.1038/nrd2482 · DOI
  38. Bryceson, 2009, Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors., Blood, 114, 2657, 10.1182/blood-2009-01-201632 · DOI · Paper page
  39. Pende, 2005, Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112)., Blood, 105, 2066, 10.1182/blood-2004-09-3548 · DOI · Paper page
  40. Halfteck, 2009, Enhanced in vivo growth of lymphoma tumors in the absence of the NK-activating receptor NKp46/NCR1., J. Immunol., 182, 2221, 10.4049/jimmunol.0801878 · DOI · Paper page
  41. Carlsten, 2009, Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells., J. Immunol., 183, 4921, 10.4049/jimmunol.0901226 · DOI · Paper page
  42. Verhoeven, 2008, NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways., Mol. Immunol., 45, 3917, 10.1016/j.molimm.2008.06.016 · DOI
  43. Toutirais, 2009, DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vgamma9Vdelta2 T cells., Eur. J. Immunol., 39, 1361, 10.1002/eji.200838409 · DOI
  44. Thompson, 2008, Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma., J. Clin. Oncol., 26, 2034, 10.1200/JCO.2007.14.5193 · DOI · Paper page
  45. Davis, 2007, An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma., Clin. Cancer Res., 13, 3630, 10.1158/1078-0432.CCR-07-0410 · DOI · Paper page
  46. Kim, 2006, FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma., Blood, 108, 2720, 10.1182/blood-2006-01-009480 · DOI · Paper page
  47. Yu, 2009, The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells., Nat. Immunol., 10, 48, 10.1038/ni.1674 · DOI · Paper page
  48. Baury, 2003, Identification of secreted CD155 isoforms., Biochem. Biophys. Res. Commun., 309, 175, 10.1016/S0006-291X(03)01560-2 · DOI

Cited by

See all 180

Metadata

Authors
Chan, C. J., Andrews, D. M., McLaughlin, N. M., Yagita, H., Gilfillan, S., Colonna, M., & Smyth, M. J.
Venue
The Journal of Immunology
Published
2009-12-27
Volume
184
Issue
2
Pages
902-911
ISSN
  • 0022-1767 (ISSN-L)
  • 1550-6606
OpenAlex
W2118653920
Cited by
180
References
8
FWCI
3.95
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: DNAM-1/CD155 Interactions Promote Cytokine and NK Cell-Mediated Suppression of Poorly Immunogenic Melanoma Metastases. https://app.cochat.ai/papers/10.4049/jimmunol.0903225
The paper
Chan, C. J., Andrews, D. M., McLaughlin, N. M., Yagita, H., Gilfillan, S., Colonna, M., & Smyth, M. J. (2010). DNAM-1/CD155 Interactions Promote Cytokine and NK Cell-Mediated Suppression of Poorly Immunogenic Melanoma Metastases. The Journal of Immunology. https://doi.org/10.4049/jimmunol.0903225

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.